Reviewing iSpecimen (NASDAQ:ISPC) and Oncology Institute (NASDAQ:TOI)

iSpecimen (NASDAQ:ISPC) and Oncology Institute (NASDAQ:TOI) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their analyst recommendations, valuation, profitability, dividends, earnings, institutional ownership and risk.

Volatility & Risk

iSpecimen has a beta of 1.81, suggesting that its stock price is 81% more volatile than the S&P 500. Comparatively, Oncology Institute has a beta of 0.08, suggesting that its stock price is 92% less volatile than the S&P 500.

Profitability

This table compares iSpecimen and Oncology Institute’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
iSpecimen	-172.48%	-395.15%	-121.72%
Oncology Institute	-14.26%	-1,527.21%	-34.25%

Institutional and Insider Ownership

13.6% of iSpecimen shares are owned by institutional investors. Comparatively, 36.9% of Oncology Institute shares are owned by institutional investors. 12.2% of iSpecimen shares are owned by company insiders. Comparatively, 8.5% of Oncology Institute shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Recommendations

This is a breakdown of current ratings for iSpecimen and Oncology Institute, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
iSpecimen	1	0	0	0	1.00
Oncology Institute	1	0	2	1	2.75

Oncology Institute has a consensus target price of $7.00, indicating a potential upside of 64.32%. Given Oncology Institute’s stronger consensus rating and higher probable upside, analysts plainly believe Oncology Institute is more favorable than iSpecimen.

Earnings & Valuation

This table compares iSpecimen and Oncology Institute”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
iSpecimen	$9.29 million	0.49	-$12.50 million	($9.51)	-0.09
Oncology Institute	$393.41 million	1.01	-$64.66 million	($0.68)	-6.26

iSpecimen has higher earnings, but lower revenue than Oncology Institute. Oncology Institute is trading at a lower price-to-earnings ratio than iSpecimen, indicating that it is currently the more affordable of the two stocks.

Summary

Oncology Institute beats iSpecimen on 10 of the 15 factors compared between the two stocks.

About iSpecimen

iSpecimen Inc. provides technology that connects life science researchers who need human biofluids, tissues, and living cells for their research with biospecimens available in healthcare provider organizations worldwide. Its cloud-based technology enables scientists to search for specimens and patients across a network of hospitals, clinics, private practice groups, laboratories, blood centers, biobanks, clinical research sites, and cadaveric donation centers. The company develops and operates iSpecimen Marketplace, a proprietary online marketplace platform that connects medical researchers who need access to subjects, samples, and data with hospitals, laboratories, and other organizations who have access to them. It serves biopharmaceutical companies, in vitro diagnostic companies, and government/academic institutions. iSpecimen Inc. was incorporated in 2009 and is headquartered in Lexington, Massachusetts.

About Oncology Institute

The Oncology Institute, Inc., an oncology company, provides various medical oncology services in the United States. The company operates through three segments: Dispensary, Patient Services, and Clinical Trials & Other. It offers physician services, in-house infusion and dispensary, clinical trial, radiation, outpatient blood product transfusion, and patient support services, as well as educational seminars, support groups, and counseling services. The company also provides managing clinical trials, palliative care programs, stem cell transplants services, and other care delivery models associated with non-community-based academic and tertiary care settings; and conducts clinical trials for a range of pharmaceutical and medical device companies. It serves adult and senior cancer patients. The company has a strategic collaboration with Healthly Forge to offer cancer care services to patients in Southern California. The Oncology Institute, Inc. was founded in 2007 and is headquartered in Cerritos, California.